Primecap Management Co. CA cut its position in Pfenex Inc (NYSEAMERICAN:PFNX) by 0.2% during the first quarter, Holdings Channel reports. The firm owned 3,341,600 shares of the biotechnology company’s stock after selling 6,300 shares during the quarter. Primecap Management Co. CA owned 0.11% of Pfenex worth $20,651,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in PFNX. Norges Bank purchased a new position in shares of Pfenex in the 4th quarter valued at $976,000. RK Capital Management LLC purchased a new position in shares of Pfenex in the 1st quarter valued at $1,864,000. BlackRock Inc. grew its position in shares of Pfenex by 4.6% in the 1st quarter. BlackRock Inc. now owns 1,697,410 shares of the biotechnology company’s stock valued at $10,489,000 after buying an additional 74,836 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Pfenex by 9.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 740,288 shares of the biotechnology company’s stock valued at $4,575,000 after buying an additional 64,242 shares during the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Pfenex by 103.7% in the 1st quarter. Wells Fargo & Company MN now owns 123,441 shares of the biotechnology company’s stock valued at $763,000 after buying an additional 62,852 shares during the last quarter.

PFNX has been the topic of a number of recent analyst reports. Wedbush reaffirmed an “outperform” rating on shares of Pfenex in a research report on Thursday, March 7th. William Blair reaffirmed an “outperform” rating on shares of Pfenex in a research report on Tuesday, March 12th. Finally, Zacks Investment Research raised shares of Pfenex from a “hold” rating to a “buy” rating and set a $5.50 target price on the stock in a research report on Friday, March 15th.

NYSEAMERICAN:PFNX traded up $0.16 during trading hours on Friday, reaching $6.94. 63,395 shares of the company’s stock were exchanged, compared to its average volume of 145,738. Pfenex Inc has a 1-year low of $3.13 and a 1-year high of $7.40.

Pfenex (NYSEAMERICAN:PFNX) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.13. The business had revenue of $10.36 million for the quarter, compared to analyst estimates of $5.63 million.

TRADEMARK VIOLATION WARNING: “Pfenex Inc (NYSEAMERICAN:PFNX) Holdings Lowered by Primecap Management Co. CA” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/pfenex-inc-nyseamericanpfnx-holdings-lowered-by-primecap-management-co-ca/3042591.html.

Pfenex Profile

Pfenex Inc, a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study.

Recommended Story: Stock Symbols and CUSIP Explained

Want to see what other hedge funds are holding PFNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfenex Inc (NYSEAMERICAN:PFNX).

Institutional Ownership by Quarter for Pfenex (NYSEAMERICAN:PFNX)

Receive News & Ratings for Pfenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex and related companies with MarketBeat.com's FREE daily email newsletter.